We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Avino Silver and Gold Mines Ltd | AMEX:ASM | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.01 | 65 | 09:00:01 |
RNS Number:4473S Antisoma PLC 25 November 2003 Antisoma and EMD Lexigen announce progress on joint anti-cancer development programme (ATTACK) 25 November 2003, London, UK and Boston, USA: Antisoma plc (LSE:ASM), the UK-based biopharmaceutical company specialising in the development of novel anti-cancer drugs, and EMD Lexigen Research Center, the US-based biotechnology company, today announce that they have co-developed a novel cancer therapy based on the application of Lexigen's immunocytokine technology and using Antisoma's antibody huBC1 and the anti-tumour cytokine IL12. The companies describe this approach as ATTACK (Anti-tumour Therapy with Targeting Antibodies and CytoKines). EMD Lexigen and Antisoma have created an immunocytokine fusion protein incorporating huBC1 and IL12. This protein has been shown to have anti-tumour effects in animal models of several different cancers. Work from the companies' collaboration is being submitted for detailed presentation at forthcoming scientific congresses. IL12, when given alone, is known to have potent effects on tumours. Early-phase safety trials provided evidence of IL12 activity against renal cell carcinomas and melanomas. However, intravenous administration of IL12 has been associated with severe and often treatment-limiting side effects. Combining IL12 with a cancer-targeting antibody is a potential way to harness its anti-tumour properties while minimising side effects, as a targeted therapy can be given at lower doses and could act more specifically on tumours. The huBC1 antibody targets oncofoetal fibronectin, a molecule associated with new tumour blood vessels. This antibody therefore provides a vehicle with the potential to deliver IL12 specifically to tumours. Glyn Edwards, CEO of Antisoma, said, "We are delighted to be collaborating with a partner of Lexigen's calibre, and are now working with them to identify the best way to move the promising new ATTACK approach rapidly into clinical trials." Stephen Gillies, President of EMD Lexigen and Global Head of Oncology Research for Merck KGaA, said, "Immunocytokine technology lends itself to many approaches through different combinations of antibodies and cytokines. We are excited to work with the novel targeting concept of Antisoma to create an innovative approach to cancer therapy." -ends- Enquiries Antisoma plc Tel: +44 (0)20 8799 8200 Glyn Edwards, Chief Executive Officer EMD Lexigen Tel: +1 919-401-7200 David Reeder Financial Dynamics Ben Atwell/Sarah MacLeod Tel: +44 (0)20 7831 3113 Notes to Editors About Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. The Company fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Antisoma forms partnerships with pharmaceutical companies to bring its products to market. In November 2002, Antisoma signed a ground-breaking collaboration agreement with Roche to develop and commercialise products from Antisoma's pipeline. Please visit www.antisoma.com for further information. About EMD-Lexigen Research Center EMD Lexigen Research Center is a research-driven company focused on developing new generations of therapies for cancer and other serious and life-threatening diseases. EMD Lexigen is a subsidiary of Merck KGaA, Darmstadt, Germany. Its research center, located in the Route 128 Biotech Corridor near Boston, Mass., is a hub for Merck KGaA's biological pharmaceutical research activities, emphasizing advanced pharmaceutical platform technologies and novel drugs. About Merck KGaA With more than 34,500 employees in 53 countries, Merck KGaA of Darmstadt, Germany, generated sales of EUR 7.5 billion in 2002. Founded in 1668 in Darmstadt, the company aims to be a world leader within its core businesses of pharmaceuticals and chemicals. Merck groups its operating activities under Merck KGaA, in which the Merck family holds 74% and the remaining 26% is publicly traded. The former U.S. subsidiary, Merck & Co., has been a completely independent company since 1917. This information is provided by RNS The company news service from the London Stock Exchange END MSCDXBDBCXDGGXS
1 Year Avino Silver and Gold Mi... Chart |
1 Month Avino Silver and Gold Mi... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions